Introduction: Whether statin use after first venous thrombosis reduces the risk of
| INTRODUCTION
Venous thrombosis (ie, deep vein thrombosis (DVT) and pulmonary embolism) is a common, serious disorder with potentially fatal outcome. The rate of recurrence in patients with a first venous thrombosis is approximately 3-5% per year, and the 30-day mortality rate is around 6%. 1, 2 Currently, the only effective strategy to prevent recurrent venous thrombosis is to continue anticoagulation indefinitely. However, treatment with anticoagulants carries a risk of major bleeding complications, and new treatment modalities with a better benefit-harm relationship are needed for long-term secondary prevention of recurrent venous thrombosis.
The observed association between venous and arterial thrombosis led to the hypothesis that pharmacological interventions that decrease the risk of arterial thrombosis would also decrease the risk of venous thrombosis. 3, 4 Statins are efficient drugs used in primary and secondary prevention of arterial thrombosis. 5, 6 Recent studies, including randomized trials, have reported that statin use may be associated with up to 40% reduced risk of first venous thrombosis, 7 which association seemed dependent on the type of statin and the clinical features of the population studied. 8, 9 The clinical utility of statins in primary prevention of venous thrombosis will be low, since the small absolute benefit of statin treatment is likely to be counteracted by similar or even more harmful side-effects, such as incident diabetes 5, 10 or rhabdomyolysis. 11 However, the net benefit of statins may be higher in high-risk groups, such as patients after a first venous thrombosis, and therefore, statins may potentially be useful in secondary prevention of venous thrombosis.
A few observational studies have tried to assess the impact of statin use on recurrent venous thrombosis, with diverging results. Biere-Rafi et al. reported a 50% reduced risk of recurrent pulmonary embolism in statin users compared with non-users. 12 Moreover, a 26% lower risk of recurrent venous thrombosis was found in a Danish registry-based study, 13 and a 17% lower risk of recurrence was reported among incident statin users vs non-users. 14 In contrast, Delluc et al. reported no association between statin intake and recurrent venous thrombosis. 15 Several methodological aspects of these studies warrant consideration, such as the selection of comparison groups, low statistical power, lack of information on important confounders, and particularly that the majority of the studies did not distinguish between incident and prevalent statin use which may have introduced "incidence/prevalence bias." 16 Since the role of statins in the prevention of venous thrombosis remains unclear, we set out to determine the association between statin use (both incident and prevalent use) and the risk of recurrent venous thrombosis in a follow-up study of patients who had previously participated in a large population-based case-control study into risk factors for a first venous thrombotic event. Detailed clinical information was available for each individual, which facilitated control for confounding.
| METHODS

Patients were recruited from the Multiple Environmental and Genetic
Assessment of risk factors for venous thrombosis (MEGA) study. 17, 18 In MEGA, patients with a first, objectively confirmed episode of venous thrombosis were recruited from 6 anticoagulation clinics in the Netherlands between March 1999 and September 2004, and 86% of the eligible patients participated. Only patients aged older than 18 years and younger than 70 years were included. In the Netherlands, patients with a thrombotic event are treated at anticoagulation clinics, which are regionally organized. Therefore, all patients living in a certain area are monitored and followed-up by the same clinic, irrespective of the hospital they were admitted to or the physician who started the treatment, allowing population-based studies.
Patients with a deep vein thrombosis of the leg, pulmonary embolism, or both were included, and patients with an upper extremity venous thrombosis were excluded. A total of 4,956 patients were eligible for the follow-up study. Of these, 225 indicated that they did not want to participate in a follow-up study, and were therefore excluded ( Figure 1 ). The study was approved by the medical ethics committee of the Leiden University Medical Center and all participants gave their written informed consent.
| Initial questionnaire (baseline characteristics)
Participants were asked to fill in a standardized questionnaire within a few weeks after enrollment in the study. Individuals who could be uniquely identified by these criteria were included in our study, ie, patients with information leading to the iden- 
| Assessment of recurrent venous thrombosis
Information about potential recurrences was retrieved from the anti- did not respond to the questionnaire or phone interview, they were censored from the last date we knew them to be recurrence-free (ie, last visit to the anticoagulation clinic or last moment the patient was known to be recurrence-free from information of the MEGA casecontrol study. The analyses were limited to certain recurrent events only, and patients with uncertain recurrent events were censored at that time.
Statistical analyses were performed with STATA version 13.0 (Stata Corporation, College Station, TX, USA). Crude incidence rates (IR) of recurrent venous thrombosis were calculated and expressed as number of events per 1,000 person-years at risk. Cox proportional hazard regression models were used to obtain hazard ratios (HR) for recurrence with 95% confidence intervals (CI). Two analyses were conducted. First, an analysis in which prevalent and incident statin users were combined, and in which statin treatment was entered in the model as a time-varying covariable. 21 This analysis should give a similar estimate of a statin effect to that obtained by an incident-user analysis when the effect is relatively constant over time 22 ; however, whether statin's effects on thrombosis risk vary with time is unclear.
To test the assumption of a constant effect of statin use to thrombosis risk, we therefore performed a second analysis that was restricted to new users only.
Adjustments for confounding were conducted using 2 different approaches: (1) a multivariable model that included age, sex, body mass index and smoking, and (2) a propensity score model. In contrast to standard adjustment techniques, where usually confounders that are thought to be related to both exposure (statin use) and outcome (recurrent thrombosis) are included in the model, selection of variables in a propensity score includes both confounders and those that are thought to be related to the outcome only. 23 Therefore, the propensity score included the aforementioned confounders and also physical inactivity, history of CVD, cancer, factor V Leiden, and blood group non-O. The propensity score was calculated by a probit regression model using the "pscore" program in STATA. The derived propensity scores were divided into 5 blocks, and the balancing properties within categories were satisfied. The propensity scores were used in the analyses as an adjusting covariable.
In a second separate analysis, we estimated the risk of recurrence in statin vs non-statin users when follow-up time was calculated from the date of withdrawal of anticoagulant treatment.
| RESULTS
In total, 2,547 (53.8%) MEGA patients with a first venous thrombosis were uniquely linked to the SFK registry (Figure 1 ). Baseline characteristics did not differ between those who were and were not linked (Table 1) , which indicates a low likelihood of selection bias in the linkage process.
During a total of 12 622 person-years of follow-up (median follow-up time 5.7 years), statin therapy was continued in 153 (6.0%) and newly initiated in 233 (9.1%) of the 2,547 patients. Baseline characteristic of patients who did and did not start to use statins during follow-up are presented in Table 2 . Statin starters were older and more frequently men, more overweight and obese, and a higher proportion had a history of arterial thrombosis than those who did not use statins.
Moreover, the proportion of patients with a first unprovoked event and the proportion with a first pulmonary embolism were higher among those who started to use statins than among those who did not.
There were 367 recurrent venous thrombotic events (overall crude incidence rate: 2.9, CI 95: 2.6-3. In general, the risk estimates were attenuated when prevalent users were also included in the analyses (Table 3 ). The risk estimates did not materially change when follow-up was restricted to the time after anticoagulation withdrawal (Table S1 ).
| DISCUSSION
Statin use appeared to be associated with a reduced risk of recurrent venous thrombosis, but not in patients with a first unprovoked event or in patients with a first pulmonary embolism. However, the confidence intervals were wide due to limited study power, and our findings should therefore be interpreted with caution.
Previous studies on the association between statin use and risk of venous thrombosis recurrence have reported somewhat diverging results. A French study of 432 patients with a first unprovoked venous thrombosis, followed for a median of 29.5 months, found no association between statin use and risk of recurrence. 15 In contrast, a Dutch register-based study of 3,093 patients hospitalized for pulmonary embolism followed for a median of 4 years found that statin use was associated with 50% reduction of recurrent pulmonary embolism. 12 A register-based study from Denmark, which included 44,330 patients with venous thrombosis followed for a median of 3 years, found that prevalent statin use was associated with a 26% reduced risk of venous thrombosis. 13 In this study, statin use appeared to have more influence on the risk of recurrent DVT (34% reduced risk), while the risk of recurrent pulmonary embolism was only modestly reduced (13%). 13 Another publication based on Danish registry data, showed that the adjusted hazard ratio for recurrent venous thrombosis was 0.83 (CI 95: 0.45-1.52) in incident statin users vs non-users. 14 In a recent study from the US, Smith and colleagues reported that statin users had 26% lower risk of recurrence than non-users, and that the effect was stronger among patients without previous CVD (38%). 24 Even though randomized clinical trials are the preferred strategy to determine effectiveness and safety of drug interventions, much information can be derived from observational studies. However, in order to get the most valid results, observational studies should attempt to mimic clinical trials. In our study, the underlying research question at hand was "should patients with a first venous thrombosis start using statins to prevent recurrence?" Because of this, we conducted our analyses both with patients who were already using statins at baseline and in analyses restricted to those who started statins. Most previous studies on statin use and recurrent venous thrombosis included both prevalent and incident statin users. [12] [13] [14] [15] Prevalent users have by definition responded and survived treatment without major side-effects.
Therefore, if statin reduces the risk of venous thrombosis, the group of prevalent users will be enriched with healthier patients, and inclusion of prevalent users will introduce a selection bias that is likely to overestimate a possible protective effect. 16 Moreover, since confounders are measured after treatment initiation in prevalent users, residual confounding will bias the results when the treatment affects these confounders. 25 Contrary to this, we found that the risk estimates pointed towards a stronger association in subjects who started statins than in those who were already on statins (prevalent users). Our study population consisted of relatively young subjects (18-70 years), and since the guidelines for prescribing statins differs with regards to age, 26 use of statins in this young population may not necessarily reflect healthy users in the same way as in the elderly. Moreover, prevalent users have reached the thrombosis threshold 27 and developed a first venous thrombosis despite the fact that they were using statins, and could therefore be more likely to get a recurrence when on statins. Our findings are supported by the study by Smith et al., 24 who also reported a stronger association when the analyses were restricted to incident statin users. The previous studies on statins and venous thrombosis recurrence showed diverging results. Some of these differences may be explained by differences in study design and study population. The most pronounced protective effect of statin use was found in the Dutch study of patients hospitalized for pulmonary embolism, 12 which contrasts our finding of no apparent association between statins and pulmonary embolism. In addition to including prevalent statin users, which may have overestimated the positive effect in this study, the patients were censored after their last prescription. 12 The latter indicates that patients for whom medications were no longer collected from a community pharmacy (ie, the healthier or perhaps terminally ill patients)
were censored during follow-up. Since statin users use a prescription drug by definition, it is likely that more non-statin users were removed from the study, and this may have introduced selection bias that obscured the true effect. Although our results on statin use were insufficiently powered to draw definite conclusions, the risk estimates obtained for incident users in our study are similar to those of the large Danish registry-based studies, 13, 14 and the studies from the US 24 and
Canada. 28 The study by Delluc et al. 15 the confidence intervals were wide, the point estimates indicated no association between statin use and risk of recurrence in those with an unprovoked first event or those with a first pulmonary embolism.
This latter finding sheds doubt on the existence of a true association between statin use and the risk of recurrent thrombosis. A large metaanalysis of venous thrombosis cohorts is warranted to further investigate the association between incident statin use and risk of recurrent venous thrombosis.
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